NASDAQ: INVA

Innoviva, Inc.

Healthcare | Biotechnology

No licensed closing price on file for INVA. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$4.35

Innoviva, Inc. (NASDAQ: INVA) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 09:59 UTC.

What Innoviva, Inc. does

Innoviva is a biopharmaceutical company with three main business areas: a royalties portfolio of respiratory products developed with GSK including RELVAR/BREO ELLIPTA and ANORO ELLIPTA, a wholly owned critical care and infectious disease platform called Innoviva Specialty Therapeutics with five approved and marketed hospital-focused products, and strategic healthcare investments including a stake in bacteriophage developer Armata Pharmaceuticals.

Summarized from Innoviva, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	10-Q 2026-08-05
EPS (TTM)	$4.35
Return on equity	23.12%
Debt/equity	0.21

Revenue Trend

Annual Revenue · Open in Platform →

Net income for FY2021, FY2022, FY2023, FY2024, FY2025 is the filer’s available-to-common figure (net of preferred dividends) — the filer tags no parent net income for those years.

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-08-24

2026-08-24Chief Accounting OfficerTax withholding-1,127$23.7K
2026-08-24Chief Executive OfficerTax withholding-1,130$23.7K
2026-08-24Chief Financial OfficerTax withholding-558$11.7K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

BlackRock, Inc.11,555,209$262.42M+45.7%
DIMENSIONAL FUND ADVISORS LP4,494,053$102.06M+1.3%
VANGUARD PORTFOLIO MANAGEMENT LLC4,220,273$95.84M-0.1%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-05-18Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-04-30Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2023-08-25Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Innoviva Inc (NASDAQ:INVA): A Decent Value Stock With an Undervalued Earnings Profile
ChartMill2026-10-20
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
Yahoo2026-10-19
Do Options Traders Know Something About Innoviva Stock We Don't?
Yahoo2026-10-12
INVA vs. MRK: Which Stock Is the Better Value Option?
zacks.com2026-10-08
Should Value Investors Buy Innoviva (INVA) Stock?
Yahoo2026-10-08

Questions this page answers

What does Innoviva, Inc. do?

Innoviva, Inc. is a biotechnology company, listed on NASDAQ as INVA.

When did INVA last file with the SEC?

Innoviva, Inc.'s most recent SEC filing on record is a 10-Q filed 2026-08-05. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 09:59 UTC. This page is also available as JSON at /api/data?ticker=INVA and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for INVA and 5,000+ tickers.

Create a free account — keep INVA

For your agent

GET /api/data?ticker=INVA

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt